Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemotherapy for operable esophageal squamous cell carcinoma
NCT04225364Phase 2Completed
- Sponsor
- Guangzhou Institute of Respiratory Health
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Guangzhou Institute of Respiratory Health. Primary endpoint: Pathologic Complete Remission. Started Jan 2020; status: completed.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04225364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225364.